Long Ideas - Achillion Pharmaceuticals (ACHN) reported positive clinical trial results for ACH-3102, the company’s NS5A inhibitor for hepatitis C (HCV). Achillion remains a leading independent mid-stage biotech … Continue Reading
Read nowLong Ideas - With Gilead’s (NASDAQ:GILD) reported 100% Hepatitis C virologic response rate over the weekend, rivals Achillion (NASDAQ:ACHN) and Vertex (NASDAQ:VRTX) traded down 15% and 5% respectively … Continue Reading
Read nowLong Ideas - Achillion Pharmaceuticals (NASDAQ:ACHN) is up nearly 80% since its summer lows (see our initial article on ACHN here), as the hepatitis C (HCV) space continues … Continue Reading
Read nowLong Ideas - After Bristol-Myers Squibb (NYSE:BMY) discontinued development of BMS-986094, once a promising nucleotide type drug for hepatitis C (HCV), in August, funds invested in this drug … Continue Reading
Read nowLong Ideas - A Bloomberg article today illustrates the Street’s bullish outlook on Achillion Pharmaceuticals (NASDAQ:ACHN) as a takeover candidate. Following the failure of Hep C compounds being developed … Continue Reading
Read now- VRTX missed second quarter earnings by a wide margin on the top- and bottom lines. The company reported EPS of $0.46, nearly half of what … Continue Reading
Read nowInsights - Yesterday after market, Achillion (ACHN) released data and a strategic update, including interim data for C3G and PNH indications. The stock was down 20% leading up to … Continue Reading
Read now
